ELAVL1 and neoplasm: In contrast, all littermate control animals were able to control RMA.ΔTAP2 tumors, while all PK136-treated and over 80% of HuR CKO animals succumbed to the tumor challenge (Fig. 6 D and Fig. S5 C), demonstrating that HuR is also required for NK cell–mediated control of MHC-I–deficient tumors.